[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
About the Journal
Editorial Board
Aims& Scopes
Journal News
Articles archive::
All Issues
Current Issue
Publication Ethics::
Peer Review Process::
Indexing Databases::
For Authors::
Authors Guideline
Call for Papers
Submission Instruction
Review Process
Research Ethics Statements
Ethical issues
Author Complaint Process
For Reviewers::
Reviewers Section
Subscription::
Registration Information
Subscription Form
Contact us::
Contact Information
Contact us
Site Facilities::
Site map
Search contents
FAQ
Top 10 contents
Inform to friends
::
Google Scholar Metrics

Citation Indices from GS

AllSince 2019
Citations68044041
h-index2721
i10-index20498
..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Registered in

AWT IMAGE

AWT IMAGE
..
:: Volume 32, Issue 4 (9-2024) ::
Journal of Ilam University of Medical Sciences 2024, 32(4): 110-121 Back to browse issues page
Prevalence of Cognitive Disorders in Multiple Sclerosis Patients: A Cross-sectional Study in Semnan in 2019
Negin Rahnama1 , Afshin Samaei2 , Majid Mirmohammadkhani3 , Saeed Kaboli4 , Nilufar Safaie * 5
1- Dept of Psychiatry, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran
2- Dept of Internal Medicine, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran
3- Dept of Community Medicine, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran
4- Dept of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
5- Dept of Psychiatry, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran , nilufar.safaei20@gmail.com
Abstract:   (167 Views)
Introduction:  Multiple sclerosis (MS) as a chronic inflammatory disease is one of the most common neurological diseases characterized by demyelinating lesions in the brain, spinal cord, and optic nerve. The present study was designed and conducted to investigate the prevalence of cognitive disorders in patients with MS.
Materials & Methods: In this cross-sectional study, 60 patients with MS referred to Kowsar Semnan Hospital (Semnan, Iran) in 2020 were examined. Two questionnaires, including Beck's Depression Inventory (BDI-II) and Brief International Cognitive Assessment for MS (BICAMS) were used for data collection. Moreover, data was entered and analyzed in STATA software (version 14).
Results: The mean (standard deviation [SD]) age of the patients was 35.33 (7.20) years; 66.7% of them were female, 85% had a university education level, 75% were married, and 16.7% experienced mild depression based on the BDI-II. In terms of the type of MS, 88.3% of patients had relapsing-remitting multiple sclerosis (RRMS) and 58.3% suffered from at least one cognitive disorder, as well as the Auditory/Verbal learning was the most common cognitive disorder with 43.3%. Women were significantly more likely than men to suffer from at least one cognitive disorder (P<0.05), and people with secondary progressive multiple sclerosis (SPMS) were significantly more likely to have at least one cognitive disorder compared to those with RRMS (P<0.05).  Similarly, the symbol digit modalities test (SDMT) scores in individuals with SPMS were significantly higher than those in individuals with RRMS (P<0.05). However, no statistically significant association was observed between the types of cognitive disorders in MS patients and the presence of depression (P>0.05).
Conclusion: A significant proportion of MS patients had at least one of the cognitive disorders, and the prevalence of cognitive disorders in SPMS patients was higher than in RRMS patients.
Keywords: Prevalence, Cognitive impairment, Multiple sclerosis, Cross-sectional study
Full-Text [PDF 796 kb]   (89 Downloads)    
Type of Study: Research | Subject: immunology
Received: 2023/09/26 | Accepted: 2024/05/1 | Published: 2024/09/22
References
1. Hauser SL, Cree BA. Treatment of multiple sclerosis: a review. Am J Med 2020;133:1380-90. e2. doi: 10.1016/j.amjmed.2020.05.049 .
2. Warren S. Epidemiology of multiple sclerosis. Neuroepidemiology: CRC Press; 2019. p. 239-64. doi:10.1016/j.ncl.2016.06.016 .
3. Magyari M, Sorensen PS. The changing course of multiple sclerosis: rising incidence, change in geographic distribution, disease course, and prognosis. Curr Opin Neurol 2019;32:320-6 .doi: 10.1097/WCO.0000000000000695 .
4. Azami M, YektaKooshali MH, Shohani M, Khorshidi A, Mahmudi L. Epidemiology of multiple sclerosis in Iran: A systematic review and meta-analysis. PLoS One 2019;14:e0214738 .doi: 10.1371/journal.pone.0214738.
5. Heydarpour P, Khoshkish S, Abtahi S, Moradi-Lakeh M, Sahraian MA. Multiple sclerosis epidemiology in Middle East and North Africa: a systematic review and meta-analysis. Neuroepidemiology 2015;44:232-44 .doi: 10.1159/000431042.
6. Elhami S-R, Mohammad K, Sahraian MA, Eftekhar H. A 20-year incidence trend (1989–2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study. Neuroepidemiology 2011;36:141-7 .doi: 10.1159/000324708.
7. Bagherieh S, Mirmosayyeb O, Vaheb S, Afshari-Safavi A, Barzegar M, Ashtari F, et al. Prevalence and Incidence of Multiple Sclerosis in Isfahan Province, Iran: A 25-Year Population-Based Study. Mult Scler Relat Disord 2023;71:104310 .doi: 10.1016/j.msard.2022.104310.
8. Saadatnia M, Etemadifar M, Maghzi AH. Multiple sclerosis in Isfahan, Iran. Int Rev Neurobiol 2007;79:357-75 .doi: 10.1016/S0074-7742(07)79016-5.
9. Alfredsson L, Olsson T. Lifestyle and environmental factors in multiple sclerosis. Cold Spring Harb Perspect Med 2019;9. doi: 10.1101/cshperspect.a028944.
10. Land WG. Role of DAMPs and cell death in autoimmune diseases: the example of multiple sclerosis. Genes Immun 2023;24:57-70 .doi: 10.1038/s41435-023-00198-8.
11. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA 2021;325:765-79 .doi: 1001/jama.2020.26858.
12. Baumstarck K, Boyer L, Boucekine M, Michel P, Pelletier J, Auquier P. Measuring the quality of life in patients with multiple sclerosis in clinical practice: a necessary challenge. Mult Scler Int 2013; 2013 .doi: 10.1155/2013/524894.
13. Pape K, Tamouza R, Leboyer M, Zipp F. Immunoneuropsychiatry—novel perspectives on brain disorders. Nat Rev Neurol 2019;15:317-28 .doi: 10.1038/s41582-019-0174-4.
14. Matute-Blanch C, Montalban X, Comabella M. Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. Handb Clin Neurol 2018;146:67-84 . doi: 10.1016/B978-0-12-804279-3.00005-8.
15. Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, Hernández Pérez MÁ, Meca-Lallana V, Ramió-Torrentà L. Cognitive dysfunctions and assessments in multiple sclerosis. Front Neurol 2019;10:581 .doi: 10.3389/fneur.2019.00581.
16. Möller A, Wiedemann G, Rohde U, Backmund H, Sonntag A. Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand 1994;89:117-21. doi: 10.1111/j.1600-0447.1994.tb01497.x.
17. Schoonheim MM, Hulst HE, Landi D, Ciccarelli O, Roosendaal SD, Sanz-Arigita EJ, et al. Gender-related differences in functional connectivity in multiple sclerosis. Mult Scler 2012;18:164-73. doi: 10.1177/1352458511422245.
18. Drulovic J, Kisic-Tepavcevic D, Pekmezovic T. Epidemiology, diagnosis and management of sexual dysfunction in multiple sclerosis. Acta Neurol Belg 2020;120:791-7 .doi: 10.1007/s13760-020-01323-4.
19. Alsaadi T, El Hammasi K, Shahrour TM, Shakra M, Turkawi L, Mudhafar A, et al. Prevalence of depression and anxiety among patients with multiple sclerosis attending the MS clinic at Sheikh Khalifa Medical City, UAE: Cross-Sectional Study. Mult Scler Int 2015; 2015:487159. doi: 10.1155/2015/487159.
20. Hsu W-Y, Cheng C-H, Zanto TP, Gazzaley A, Bove RM. Effects of transcranial direct current stimulation on cognition, mood, pain, and fatigue in multiple sclerosis: a systematic review and meta-analysis. Front Neurol 2021;12:626113.doi: 10.3389/fneur.2021.626113 .
21. Leshno A, Sagiv O, Aloni R, Skaat A, Achiron A, Huna-Baron R, et al. Cognitive Performance of Patients With Multiple Sclerosis and Optic Neuritis at Presentation. J Neuroophthalmol 2022;42:e8-e13 . doi: 10.1097/WNO.0000000000001245.
22. Carotenuto A, Costabile T, Pontillo G, Moccia M, Falco F, Petracca M, et al. Cognitive trajectories in multiple sclerosis: a long-term follow-up study. Neurol Sci 2022;43:1215-22. doi: 10.1007/s10072-021-05356-2 .
23. Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R, et al. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler 2017;23:721-33. doi: 10.1177/1352458517690821.
24. Beier M, Hughes AJ, Williams MW, Gromisch ES. Brief and cost-effective tool for assessing verbal learning in multiple sclerosis: Comparison of the Rey Auditory Verbal Learning Test (RAVLT) to the California Verbal Learning Test–II (CVLT-II). J Neurol Sci 2019;400:104-9. doi: 10.1016/j.jns.2019.03.016.
25. Hassanshahi E, Asadollahi Z, Azin H, Hassanshahi J, Hassanshahi A, Azin M. Cognitive function in multiple sclerosis patients based on age, gender, and education level. Acta Medica Iranica 2020:500-7. doi: 10.18502/acta.v58i10.4912.
26. Odintsova TA, Kopchak OO. Sleep disorders in relapsing-remitting multiple sclerosis patients. Wiad Lek 2021;74:257-62.doi: 10.1177/20552173221144229 .
27. Boeschoten RE, Braamse AM, Beekman AT, Cuijpers P, van Oppen P, Dekker J, et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci 2017;372:331-41. doi: 10.1016/j.jns.2016.11.067.
28. Ruano L, Portaccio E, Goretti B, Niccolai C, Severo M, Patti F, et al. Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler 2017;23:1258-67. doi: 10.1177/1352458516674367.
29. Planche V, Gibelin M, Cregut D, Pereira B, Clavelou P. Cognitive impairment in a population‐based study of patients with multiple sclerosis: differences between late relapsing− remitting, secondary progressive and primary progressive multiple sclerosis. Eur J Neurol 2016;23:282-9. doi: 10.1111/ene.12715.
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA

Ethics code: IR.SEMUMS.REC.1400.022

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rahnama N, Samaei A, Mirmohammadkhani M, Kaboli S, Safaie N. Prevalence of Cognitive Disorders in Multiple Sclerosis Patients: A Cross-sectional Study in Semnan in 2019. J. Ilam Uni. Med. Sci. 2024; 32 (4) :110-121
URL: http://sjimu.medilam.ac.ir/article-1-8104-en.html
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 32, Issue 4 (9-2024) Back to browse issues page
مجله دانشگاه علوم پزشکی ایلام Journal of Ilam University of Medical Sciences
Persian site map - English site map - Created in 0.15 seconds with 41 queries by YEKTAWEB 4666